Logo image of EBS

EMERGENT BIOSOLUTIONS INC (EBS) Stock Fundamental Analysis

NYSE:EBS - New York Stock Exchange, Inc. - US29089Q1058 - Common Stock - Currency: USD

7.28  +0.29 (+4.15%)

After market: 7.031 -0.25 (-3.42%)

Fundamental Rating

4

EBS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While EBS seems to be doing ok healthwise, there are quite some concerns on its profitability. EBS has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

In the past year EBS has reported negative net income.
In the past year EBS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: EBS reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: EBS reported negative operating cash flow in multiple years.
EBS Yearly Net Income VS EBIT VS OCF VS FCFEBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

1.2 Ratios

Looking at the Return On Assets, with a value of -9.23%, EBS belongs to the top of the industry, outperforming 84.59% of the companies in the same industry.
EBS has a better Return On Equity (-23.81%) than 82.44% of its industry peers.
Industry RankSector Rank
ROA -9.23%
ROE -23.81%
ROIC N/A
ROA(3y)-20.7%
ROA(5y)-8.82%
ROE(3y)-57.28%
ROE(5y)-27.44%
ROIC(3y)N/A
ROIC(5y)N/A
EBS Yearly ROA, ROE, ROICEBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80 -100

1.3 Margins

EBS has a better Gross Margin (35.33%) than 74.55% of its industry peers.
EBS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EBS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.64%
GM growth 5Y-10.6%
EBS Yearly Profit, Operating, Gross MarginsEBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

4

2. Health

2.1 Basic Checks

EBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
EBS has more shares outstanding than it did 1 year ago.
EBS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, EBS has a worse debt to assets ratio.
EBS Yearly Shares OutstandingEBS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
EBS Yearly Total Debt VS Total AssetsEBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

EBS has an Altman-Z score of 1.13. This is a bad value and indicates that EBS is not financially healthy and even has some risk of bankruptcy.
EBS has a better Altman-Z score (1.13) than 66.67% of its industry peers.
The Debt to FCF ratio of EBS is 7.05, which is on the high side as it means it would take EBS, 7.05 years of fcf income to pay off all of its debts.
EBS has a Debt to FCF ratio of 7.05. This is amongst the best in the industry. EBS outperforms 92.65% of its industry peers.
A Debt/Equity ratio of 1.20 is on the high side and indicates that EBS has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.20, EBS is doing worse than 78.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.2
Debt/FCF 7.05
Altman-Z 1.13
ROIC/WACCN/A
WACC9.85%
EBS Yearly LT Debt VS Equity VS FCFEBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

EBS has a Current Ratio of 6.32. This indicates that EBS is financially healthy and has no problem in meeting its short term obligations.
EBS has a Current ratio of 6.32. This is in the better half of the industry: EBS outperforms 63.08% of its industry peers.
EBS has a Quick Ratio of 3.51. This indicates that EBS is financially healthy and has no problem in meeting its short term obligations.
EBS's Quick ratio of 3.51 is in line compared to the rest of the industry. EBS outperforms 43.01% of its industry peers.
Industry RankSector Rank
Current Ratio 6.32
Quick Ratio 3.51
EBS Yearly Current Assets VS Current LiabilitesEBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.95% over the past year.
Looking at the last year, EBS shows a very negative growth in Revenue. The Revenue has decreased by -28.47% in the last year.
Measured over the past years, EBS shows a decrease in Revenue. The Revenue has been decreasing by -1.15% on average per year.
EPS 1Y (TTM)88.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.34%
Revenue 1Y (TTM)-28.47%
Revenue growth 3Y-16.2%
Revenue growth 5Y-1.15%
Sales Q2Q%-26.03%

3.2 Future

Based on estimates for the next years, EBS will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.93% on average per year.
Based on estimates for the next years, EBS will show a small growth in Revenue. The Revenue will grow by 7.53% on average per year.
EPS Next Y332.95%
EPS Next 2Y163.67%
EPS Next 3Y23.19%
EPS Next 5Y16.93%
Revenue Next Year-25.83%
Revenue Next 2Y-7.19%
Revenue Next 3Y-15.84%
Revenue Next 5Y7.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EBS Yearly Revenue VS EstimatesEBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
EBS Yearly EPS VS EstimatesEBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 -4 6

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EBS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 4.74, which indicates a rather cheap valuation of EBS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EBS indicates a rather cheap valuation: EBS is cheaper than 98.92% of the companies listed in the same industry.
EBS is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.52, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 4.74
EBS Price Earnings VS Forward Price EarningsEBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EBS indicates a rather cheap valuation: EBS is cheaper than 94.27% of the companies listed in the same industry.
99.10% of the companies in the same industry are more expensive than EBS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 4.19
EV/EBITDA 24.75
EBS Per share dataEBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EBS's earnings are expected to grow with 23.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y163.67%
EPS Next 3Y23.19%

0

5. Dividend

5.1 Amount

EBS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

EMERGENT BIOSOLUTIONS INC

NYSE:EBS (7/17/2025, 8:18:45 PM)

After market: 7.031 -0.25 (-3.42%)

7.28

+0.29 (+4.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-04 2025-08-04
Inst Owners67.25%
Inst Owner Change0%
Ins Owners2.75%
Ins Owner Change22.12%
Market Cap395.16M
Analysts74.29
Price Target13.77 (89.15%)
Short Float %19.02%
Short Ratio7.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)84.88%
Min EPS beat(2)59.77%
Max EPS beat(2)110%
EPS beat(4)3
Avg EPS beat(4)223.89%
Min EPS beat(4)-143.07%
Max EPS beat(4)868.88%
EPS beat(8)4
Avg EPS beat(8)66.73%
EPS beat(12)4
Avg EPS beat(12)-223.57%
EPS beat(16)6
Avg EPS beat(16)-176.87%
Revenue beat(2)1
Avg Revenue beat(2)-11.92%
Min Revenue beat(2)-24.3%
Max Revenue beat(2)0.46%
Revenue beat(4)2
Avg Revenue beat(4)1.66%
Min Revenue beat(4)-24.3%
Max Revenue beat(4)32.73%
Revenue beat(8)5
Avg Revenue beat(8)12.82%
Revenue beat(12)7
Avg Revenue beat(12)8.69%
Revenue beat(16)9
Avg Revenue beat(16)5.05%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-500%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.67%
Revenue NQ rev (1m)41.48%
Revenue NQ rev (3m)-23.43%
Revenue NY rev (1m)2.34%
Revenue NY rev (3m)-0.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 4.74
P/S 0.41
P/FCF 4.19
P/OCF 3.59
P/B 0.71
P/tB 5.85
EV/EBITDA 24.75
EPS(TTM)-0.19
EYN/A
EPS(NY)1.54
Fwd EY21.09%
FCF(TTM)1.74
FCFY23.89%
OCF(TTM)2.03
OCFY27.86%
SpS17.79
BVpS10.18
TBVpS1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.23%
ROE -23.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.33%
FCFM 9.78%
ROA(3y)-20.7%
ROA(5y)-8.82%
ROE(3y)-57.28%
ROE(5y)-27.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.64%
GM growth 5Y-10.6%
F-Score4
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 1.2
Debt/FCF 7.05
Debt/EBITDA 18.39
Cap/Depr 14.77%
Cap/Sales 1.63%
Interest Coverage N/A
Cash Conversion 304.14%
Profit Quality N/A
Current Ratio 6.32
Quick Ratio 3.51
Altman-Z 1.13
F-Score4
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)106.07%
Cap/Depr(5y)126.37%
Cap/Sales(3y)13.29%
Cap/Sales(5y)12.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.34%
EPS Next Y332.95%
EPS Next 2Y163.67%
EPS Next 3Y23.19%
EPS Next 5Y16.93%
Revenue 1Y (TTM)-28.47%
Revenue growth 3Y-16.2%
Revenue growth 5Y-1.15%
Sales Q2Q%-26.03%
Revenue Next Year-25.83%
Revenue Next 2Y-7.19%
Revenue Next 3Y-15.84%
Revenue Next 5Y7.53%
EBIT growth 1Y56.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year330.47%
EBIT Next 3Y55.51%
EBIT Next 5Y39.09%
FCF growth 1Y117.95%
FCF growth 3Y-28.05%
FCF growth 5Y-17.04%
OCF growth 1Y160.03%
OCF growth 3Y-43.25%
OCF growth 5Y-20.77%